Abstract: A hybrid material for light emitting diodes, comprising a) an organopolysilazane material, comprising repeating units of formulae (I) and (II) [—SiR1R2—NR3—]x??(I) [—SiHR4—NR5—]y??(II) wherein the symbols and indices have the following meanings: R1 is C2-C6-alkenyl or C4-C6-alkadienyl; R2 is H or an organic group; R3 is H or an organic group; R4 is H or an organic group; R5 is H or an organic group; x is 0.001 to 0.2; and y is 2x to (1?x), with the proviso that x+y?1 and that y can be 0 if R2 is H, and b) inorganic nanoparticles having a mean diameter in the range of from 1 to 30 nm, which are surface modified with a capping agent comprising a C1-C18-alkyl and/or C1-C18-alkenyl group, is useful as encapsulation material for LEDs.

Abstract: A circuit arrangement is provided for suppressing offset, offset drift, and 1/f noise during analog/digital conversion. The arrangement includes an analog/digital converter configured to convert an analog input signal into output data, an inverter configured to invert the input signal, a switching element connected upstream of the analog/digital converter and downstream of the inverter and configured to periodically change over between the input signal and the inverted input signal at a predefinable switching frequency, and a switchable negator circuit connected downstream of the analog/digital converter and configured to periodically negate the output data from the analog/digital converter at the switching frequency, the output data being negated when the inverted input signal is applied to the analog/digital converter. An analog/digital converter is also provided with suppression of offset, offset drift, and 1/f noise during analog/digital conversion.

Abstract: The invention relates to the use of specific organopolysilazanes as an encapsulation material for light emitting diodes (LED). The organopolysilazane polymers act as insulating filling materials and are stable over temperature and over exposure to ambient UV radiation. The encapsulating material has good thermal stability against discoloration to yellow by aging even at high temperatures which is a key factor for the long lifetime of an LED encapsulant and the LED performance.

Abstract: A control apparatus for a gradient amplifier includes a differentiation unit. The differentiation unit forms a differentiation signal by differential processing from a current desired value signal of the gradient amplifier. At least one electrical low pass filter unit is connected in series with the differentiation unit, and/or at least one electrical high pass filter unit is connected in parallel with the differentiation unit.

Abstract: A gradient pulse generator generates reference current signals for a plurality of gradient coils of a gradient coil system of a magnetic resonance system and supplies each of the reference current signals to a controller assigned to one of the gradient coils. Also supplied to the respective controller is an actual current signal that is characteristic of the current flowing in the respective gradient coil. Each of the controllers generates a control signal and accordingly drives a gradient power amplifier assigned to the respective gradient coil. The gradient power amplifiers apply a current to the gradient coils assigned to the gradient power amplifiers in accordance with the generated control signals. Each of the controllers is also supplied with the reference current signal or the actual current signal of at least one other gradient coil or the time derivative of the reference current signal or the actual current signal.

Abstract: A circuit arrangement is provided for suppressing offset, offset drift, and 1/f noise during analog/digital conversion. The arrangement includes an analog/digital converter configured to convert an analog input signal into output data, an inverter configured to invert the input signal, a switching element connected upstream of the analog/digital converter and downstream of the inverter and configured to periodically change over between the input signal and the inverted input signal at a predefinable switching frequency, and a switchable negator circuit connected downstream of the analog/digital converter and configured to periodically negate the output data from the analog/digital converter at the switching frequency, the output data being negated when the inverted input signal is applied to the analog/digital converter. An analog/digital converter is also provided with suppression of offset, offset drift, and 1/f noise during analog/digital conversion.

Abstract: The invention concerns a method for determining antigen-specific antibodies of a particular immunoglobulin class in a sample by means of an immunoassay in an array format in which various binding partners Bnx are bound on different discrete areas on a support where Bnx in each case contain the various antigens that are able to specifically bind to the antibodies to be detected, by incubating the support with the sample and a binding partner B2 which carries a label and subsequently detecting the label on the respective discrete areas wherein B2 specifically binds antibodies of a certain immunoglobulin class that have been bound in an antigen-specific manner.

Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

Abstract: A gradient pulse generator generates reference current signals for a plurality of gradient coils of a gradient coil system of a magnetic resonance system and supplies each of the reference current signals to a controller assigned to one of the gradient coils. Also supplied to the respective controller is an actual current signal that is characteristic of the current flowing in the respective gradient coil. Each of the controllers generates a control signal and accordingly drives a gradient power amplifier assigned to the respective gradient coil. The gradient power amplifiers apply a current to the gradient coils assigned to the gradient power amplifiers in accordance with the generated control signals. Each of the controllers is also supplied with the reference current signal or the actual current signal of at least one other gradient coil or the time derivative of the reference current signal or the actual current signal.

Abstract: A control apparatus for a gradient amplifier includes a differentiation unit. The differentiation unit forms a differentiation signal by differential processing from a current desired value signal of the gradient amplifier. At least one electrical low pass filter unit is connected in series with the differentiation unit, and/or at least one electrical high pass filter unit is connected in parallel with the differentiation unit.

Abstract: The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention discloses a method of detecting a therapeutic antibody in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to a therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody. A monoclonal antibody directed to a certain epitope that is present on all classes of human immunoglobulin of class G, but not on the immunoglobulin of any experimental animal except on the IgG of chimpanzees was used (MAB-M-R10Z8E9).

Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

Abstract: This invention relates to a composition of labeled and non-labeled monoclonal antibodies directed to a human transmembrane protein for the simultaneous treatment and diagnosis of diseases which are associated with an overexpression of such a protein especially of cancer. The invention further relates to a method of first administering said composition, determine the change of labeled antibody concentration and afterwards administering the non-labeled monoclonal antibodies only such that the minimum required concentration of such non-labeled antibody for a favorable therapeutical effect is achieved and maintained in the treatment, while unfavorable side effects are minimized due to the lower systemic antibody concentration.

Abstract: A method for generating at least one modulator input signal from at least one regulator signal is provided. The method comprising: generating at least one dither signal based on the periodic output of elements of a discrete dither sequence of the basic form DF=0, 1, 2 . . . 2(m?n)?1; and adding the at least one dither signal to the regulator signal. The regulator signal comprises a digital regulator signal with a length of m bits, and the modulator input signal comprises a digital modulator input signal with a length of n bits, where m>n.

Abstract: A power supply for at least one predominantly inductive load is provided. The power supply includes at least one controllable voltage source powered with a supply voltage, the at least one controllable voltage source supplying a controlled output voltage which powers the inductive load. The supply voltage of the voltage source is variable and the supply voltage is operable to be controlled as a function of the current flowing through the predominantly inductive load.

Abstract: By deglycosylating an enzyme derived from a eukaryotic organism prior to forming a conjugate, i.e. prior to attaching the enzyme to a molecule capable of binding to a target molecule, the sensitivity of an assay for detecting the presence or determining the quantity of a target molecule, in which the conjugate is used as a labelled component, can be increased. The present invention provides conjugates, methods for providing the same, use of such conjugates as well as kits containing the conjugates.

Abstract: A method for controlling an electric amplifier is provided. The method includes monitoring a closed-loop control signal of a regulator, which triggers an end stage of the amplifier; adjusting the closed-loop control signal as a function of an output signal of the end stage; comparing the closed-loop control signal with a reference signal; triggering the end stage when an amplitude limit value and a period length limit value are exceeded or undershot by the amplitude value and period length value, respectively, of the closed-loop control signal; and blocking an input side and/or the regulator when the end stage is triggered.

Abstract: An electrical amplifier comprising an output stage that can be supplied by an electrical energy source, is connected to a control device on the input side, the control signal of the control device controlling an output signal of the output stage dependent on a parameter value of the energy source. The amplifier is has a compensation device that is connected to the energy source and the control device, and is used to modify the control signal according to the parameter value of the energy source which can be, for example, the network voltage of the energy source. A method for controlling an electrical amplifier comprising an output stage supplied by an electrical energy source includes, determining parameter value of the energy source, deriving a compensation signal therefrom, and a control signal for the output stage is generated according to the compensation signal. The amplifier and method can be used in a gradient amplifier for a magnetic resonance appliance.

Abstract: The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention discloses a method of detecting a therapeutic antibody in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to a therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody. A monoclonal antibody directed to a certain epitope that is present on all classes of human immunoglobulin of class G, but not on the immunoglobulin of any experimental animal except on the IgG of chimpanzees was used (MAB-M-R10Z8E9).